Halyard Health (HYH) Misses Q4 EPS by 23c, Offers FY17 Guidaance
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 11/3/2026
- Nasdaq ends higher as AI heavyweights rebound ahead of midterm results
- Apple shares slip amid guidance for tightening margins, slowing services growth
- Rising shorts cool U.S. large-cap positioning, cutting liquidation risk: Citi
- Apple's 'unprecedented' memory warning adds fuel to wobbly Micron, SK hynix trade
- Palantir raises 2026 revenue outlook after quarterly revenue nearly doubles on AI
- After-Hours Movers: AMD, SMCI, SWKS, NRIX, TOST, BKNG
- After-Hours Movers: AMZN, TWLO, INTC, SNDK, RDDT, RBLX, PINS, RIVN, SBUX, ILMN
- After-Hours Movers: GOOGL, MSFT, NOW, KLAC. CMG, CVNA, TDOC
- After-Hours Movers: STX, ENPH, HOOD, V, CSGP, BOOM, CAKE, PPG, OI, TER
- After-Hours Movers: CLS, AVGO, CDNS, AMKR, WHR
Halyard Health (HYH) PT Raised to $45 at Stifel Following 4Q Beat
February 28, 2017 9:56 AM ESTStifel raised its price target on Halyard Health (NYSE: HYH) to $45.00 (from $38.00) while maintaining a Buy rating. 4Q16 EPS at $0.50 beat Stifel ($0.46) and Consensus ($0.44) estimates though a one-time tax benefit added ~$0.04.
Analyst Rick Wise commented, "HYH closed 2016 with its fourth consecutive quarter of sales and EPS upside relative to both Consensus and management guidance. After a more difficult than expected first-year (2015)... More



